FDA Fast Track designation was supported by data from a Phase 2 study reviewing pamrevlumab in combination with gemcitabine and nab-paclitaxel.
Those with pancreatic adenocarcinoma and a personal history of another cancer associated with hereditary breast and ovarian cancer or Lynch syndrome may be more likely to carry germline mutations.
Capecitabine and Oxaliplatin as First and Second Line Treatment for Locally Advanced and Metastatic Pancreatic Ductal AdenocarcinomaDecember 22, 2017
[Journal of Gastrointestinal Oncology] This research evaluates the use of capecitabine and oxaliplatin (CAPOX) for first or second-line treatment of locally advanced or metastatic PDAC.
Utilization and Trends in Palliative Therapy for Stage IV Pancreatic Adenocarcinoma Patients: A U.S. Population-based StudySeptember 29, 2017
[Journal of Gastrointestinal Oncology] This research examined patients who presented with metastatic pancreatic adenocarcinoma at diagnosis, and their patterns of palliative care utilization.
An association was found between low PNI/high CAR levels and poor outcomes in operable pancreatic ductal adenocarcinoma, even in patients who undergo curative resection.
By identifying incidence, prevalence, and risk factors for colorectal and pancreatic cancer in our communities, nurse navigators can develop screening and prevention programs to better serve these populations.
Precision Medicine Improves Pancreatic Cancer Treatment
Cisplatin plus standard-of-care gemcitabine/nab-paclitaxel improved tumor shrinkage in patients with metastatic pancreatic cancer, according to a study by the HonorHealth Research Institute and the Translational Genomics Research Institute.
Biopolymer codelivery of CAR T cells and stimulator of IFN genes directly to the surface of solid tumors more effectively reduced tumor size.
An investigation into whether onset or worsening of diabetes causes pancreatic cancer or vice versa was presented at the 2017 European Cancer Congress.
Use of Adjuvant gemcitabine plus capecitabine for patients with pancreatic cancer who have undergone tumor resection resulted in a modest increase short-term survival.
PDX1 appears to have distinct roles at different stages of pancreatic cancer development.
Seluminitinib in combination with an AKT inhibitor did not improve survival compared with modified FOLFOX in previously treated metastatic pancreatic cancer.
Favorable Perioperative Outcomes After Resection of Borderline Resectable Pancreatic Cancer Treated With Neoadjuvant Stereotactic Radiation and Chemotherapy Compared with Upfront Pancreatectomy for Resectable CancerAugust 25, 2016
[Journal of Gastrointestinal Oncology] This research examines outcomes related to the use of neoadjuvant multi-agent chemotherapy and stereotactic body radiation therapy (SBRT) in borderline resectable pancreatic cancer (BRPC) or locally advanced pancreatic cancer (LAPC) patients.
Research findings reveal the mechanism by which obesity increases inflammation and desmoplasia in the most frequent type of pancreatic cancer, using mouse models and human tissue samples.
Systematic Palliative Care Provides Greater Improvement in Quality of Life for Patients with Pancreatic CancerJuly 29, 2016
Quality of life is significantly improved for patients with pancreatic cancer when systematic palliative care is administered vs on-demand palliative care.
Metastatic capabilities of pancreatic cancer might arise before tumors even form. Metastasis and advanced stage of disease at diagnosis are attributed to low survival rates for pancreatic cancer.
Combining a laboratory ultrasound technique called sonoporation with the commercially available chemotherapy compound gemcitabine increases the porosity of pancreatic cells with microbubbles and helps get the drug into cancer cells.
Despite the increased risk, patients whose pancreatic cancer tumor has grown to encompass critical blood vessels can be candidates for surgery. Data on efforts to fine-tune a protocol for these patients were presented at the SSAT 57th Annual Meeting.
Adjuvant gemcitabine plus capecitabine significantly improved overall survival compared with gemcitabine monotherapy in patients with pancreatic ductal adenocarcinoma, according to results of the ESPAC-4 trial presented at the ASCO 2016 Annual Meeting.
Chemoradiotherapy Showed No Survival Benefit Over Chemotherapy in Locally Advanced Pancreatic CancerMay 24, 2016
Researchers discovered no survival benefit of chemoradiotherapy over chemotherapy in treating locally advanced pancreatic cancer in the LAP01 Randomized Clinical Trial.
Barriers to Understanding Pancreatic Cancer Can Be Overcome With Improvements to Online Health InformationMay 23, 2016
Available information on pancreatic cancer was written at too high a level and contained inaccuracies regarding alternative therapies, a recent study has shown.
Molecular profiling of a case of advanced pancreatic cancer identifies an active and tolerable combination of targeted therapy with backbone chemotherapyMay 19, 2016
[Journal of Gastrointestinal Oncology] This research reviews the case history of a patient with stage IVB pancreatic adenocarcinoma initially treated with gemcitabine and erlotinib who stopped therapy after 3 months without achieving a response and was switched to a different and effective combination strategy.
A small molecule that inhibits RAS protein interactions offers hope for targeting this elusive protein. It is one of the most sought-after cancer targets for drug developers, but the mutant RAS protein lacks drug-binding pockets.
Lowest accuracy scores for alternative tx websites; websites with higher accuracy more difficult to read
New research indicates a far greater efficacy in pancreatic cancer drug therapy delivered via implantable device than via IV.
An experimental therapy looks to hold promise for tumor control treatment in pancreatic adenocarcinoma.
Two strains of oral bacteria -- P. gingivalis and A. actinomycetemcomitans -- have been linked to higher risk of pancreatic cancer.
An experimental immune therapy can re-educate macrophages to tear down the scaffolding that surrounds and protects pancreatic cancer from chemotherapy.
Adding radiotherapy to chemotherapy and surgery reduced the number of local disease recurrences but did not affect distant recurrences or survival.
Sign Up for Free e-newsletters
- Study Finds Association Between Folate Intake and Risk of Cutaneous Melanoma
- Melanoma Outcomes Improved With Nivolumab Alone or Plus Ipilimumab
- Oral Contraceptive Use May Not Be Associated With Increased Melanoma Risk
- The Caregivers' Cancer Journey
- Staff Education Leads to Increase in Oncology Rehabilitation Referrals
- Implementing an Ambulatory Adherence Program May Improve Oral Anticancer Medications Compliance
- Exercise Habits Influence Mortality in Adult Survivors of Childhood Cancer
- Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life
- CALM: A Depression Intervention for Cancer Patients at the End of Life
- High BMI Among Premenopausal Women May Improve Risk for Breast Cancer
- Choice of Breast Reconstruction After Mastectomy Affects Satisfaction, Quality of Life
- Gender Bias in Medicine Has Far-Reaching Consequences
- Carfilzomib Benefits May Outweigh Cardiovascular Risk in Multiple Myeloma
- Patient Interest in Melanoma Genetic Risk Testing is Fairly High
- Genetic Link Between Depression and Breast Cancer Remains Unclear
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|